60 Degrees Pharma Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
3
- Stock Symbol
-
SXTP
- Share Price
-
$0.47
- (As of Friday Closing)
60 Degrees Pharma General Information
Description
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
Contact Information
Website
www.60degreespharma.comCorporate Office
- 1025 Connecticut Avenue North West
- Suite 1000
- Washington, DC 20036
- United States
Corporate Office
- 1025 Connecticut Avenue North West
- Suite 1000
- Washington, DC 20036
- United States
60 Degrees Pharma Timeline
60 Degrees Pharma Stock Performance
As of 20-Nov-2026, 60 Degrees Pharma’s stock price is $0.47. Its current market cap is $2.1M with 4.48M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.47 | $0.50 | $0.46 - $8.62 | $2.1M | 4.48M | 402K | -$2.77 |
60 Degrees Pharma Financials Summary
As of 30-Sep-2026, 60 Degrees Pharma has a trailing 12-month revenue of $907K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 13,288 | 7,672 | 7,599 | 13,705 |
| Revenue | 907 | 1,005 | 608 | 254 |
| EBITDA | (8,235) | (7,278) | (7,884) | (1,427) |
| Net Income | (8,349) | (7,365) | (7,947) | (3,766) |
| Total Assets | 3,094 | 5,366 | 5,759 | 7,784 |
| Total Debt | 150 | 153 | 156 | 173 |
60 Degrees Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
60 Degrees Pharma Comparisons
Industry
Financing
Details
60 Degrees Pharma Competitors (5)
One of 60 Degrees Pharma’s 5 competitors is Melinta Therapeutics, a Private Equity-Backed company based in Parsippany, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Melinta Therapeutics | Private Equity-Backed | Parsippany, NJ | ||||
| Insud Pharma | Corporation | Madrid, Spain | ||||
| AN2 Therapeutics | Formerly VC-backed | Menlo Park, CA | ||||
| Nova Biologics | Corporation | Oceanside, CA | ||||
| Ambagon Therapeutics | Venture Capital-Backed | Eindhoven, Netherlands |
60 Degrees Pharma Patents
60 Degrees Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4698164-A1 | Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof | Pending | 21-Apr-2023 | ||
| EP-4698165-A1 | Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof | Pending | 21-Apr-2023 | ||
| EP-4698167-A1 | Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof | Pending | 21-Apr-2023 | ||
| US-20240390359-A1 | Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof | Pending | 21-Apr-2023 | ||
| US-20250073222-A1 | Methods for the treatment and prevention of non-viral tick-borne diseases and symptoms thereof | Pending | 21-Apr-2023 | A61K31/4706 |
60 Degrees Pharma Signals
60 Degrees Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
60 Degrees Pharma FAQs
-
When was 60 Degrees Pharma founded?
60 Degrees Pharma was founded in 2010.
-
Where is 60 Degrees Pharma headquartered?
60 Degrees Pharma is headquartered in Washington, DC.
-
What is the size of 60 Degrees Pharma?
60 Degrees Pharma has 3 total employees.
-
What industry is 60 Degrees Pharma in?
60 Degrees Pharma’s primary industry is Drug Discovery.
-
Is 60 Degrees Pharma a private or public company?
60 Degrees Pharma is a Public company.
-
What is 60 Degrees Pharma’s stock symbol?
The ticker symbol for 60 Degrees Pharma is SXTP.
-
What is the current stock price of 60 Degrees Pharma?
As of 20-Nov-2026 the stock price of 60 Degrees Pharma is $0.47.
-
What is the current market cap of 60 Degrees Pharma?
The current market capitalization of 60 Degrees Pharma is $2.1M.
-
What is 60 Degrees Pharma’s current revenue?
The trailing twelve month revenue for 60 Degrees Pharma is $907K.
-
Who are 60 Degrees Pharma’s competitors?
Melinta Therapeutics, Insud Pharma, AN2 Therapeutics, Nova Biologics, and Ambagon Therapeutics are competitors of 60 Degrees Pharma.
-
What is 60 Degrees Pharma’s annual earnings per share (EPS)?
60 Degrees Pharma’s EPS for 12 months was -$2.77.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process